Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada

Kate Zinszer, Britt McKinnon, Noémie Bourque, Monica Zahreddine, Katia Charland, Jesse Papenburg, Geneviève Fortin, Marie-Ève Hamelin, Adrien Saucier, Alex Apostolatos, Laura Pierce, Ashley Savard-Lamothe, Julie Carbonneau, Patricia Conrod, Nancy Haley, Isabelle Laurin, Guy Boivin, Gaston De Serres, Caroline Quach

ABSTRACT

Introduction Further evidence is needed to understand the contribution of schools and daycares for the spread of COVID-19 in the context of diverse transmission dynamics and continually evolving public health interventions. The Enfants et COVID-19: Étude de séroprévalence (EnCORE) study will estimate the seroprevalence and seroconversion of SARS-CoV-2 among school and daycare children and personnel. In addition, the study will examine associations between seroprevalence and sociodemographic characteristics and reported COVID-19 symptoms and tests, and investigates changes in health, lifestyle and well-being outcomes.

Methods and analysis This study includes children and personnel from 62 schools and daycares in four neighbourhoods in Montreal, Canada. All children aged 2–17 years attending one of the participating schools or daycares and their parents are invited to participate, as well as a sample of personnel members. Participants respond to brief questionnaires and provide blood samples, collected via dried blood spot, at baseline (October 2020–March 2021) and follow-up (May–June 2021). Questionnaires include sociodemographic and household characteristics, reported COVID-19 symptoms and tests, potential COVID-19 risk factors and prevention efforts and health and lifestyle information. Logistic regression using generalised estimating equations will be used to estimate seroprevalence and seroconversion, accounting for school-level clustering.

Ethics and dissemination This study was approved by the research ethics boards of the Université de Montréal (CERSES) and the Centre Hospitalier Universitaire Sainte-Justine. Results will contribute to our knowledge about SARS-CoV-2 transmission in schools and daycares and will be made available to study participants and their families, school and public health decision-makers and the research community.

INTRODUCTION

National and subnational closures of educational institutions during the SARS-CoV-2 pandemic have affected hundreds of millions of students around the world. Certain countries have elected to keep schools mostly open (eg, Sweden, Taiwan), while others have opted for extended closures (eg, USA, India). Decisions about school and daycare closures have been guided by uncertainty around the exact role that children and adolescents play in transmission of SARS-CoV-2 infection and the extent that in-person learning contributes to epidemic spread. Conversely, governments have had to consider the adverse consequences of school closures for children’s physical, emotional and psychological well-being, as well as the economic and emotional toll on parents and school personnel.

Children and adolescents experience far lower rates of severe disease, hospitalisation and death from COVID-19 than adults, with most experiencing no or mild symptoms of infection. While children are clearly susceptible to infection, perhaps as
susceptible as adults,\textsuperscript{9,10} the role they play in transmission of the virus, particularly school settings, continues to be debated.\textsuperscript{3,4} Seroprevalence data from household and surveillance studies suggests young children probably play a lesser role in transmission than adults,\textsuperscript{11–13} while older children and adolescents may have transmission rates more similar to adults.\textsuperscript{12} Serological evidence is crucial for elucidating children’s role in SARS-CoV-2 transmission as infected children with asymptomatic or mild disease manifestation may not have been tested by PCR, but can nevertheless mount an immune response with detectable anti-SARS-CoV-2 antibodies.\textsuperscript{11} Longitudinal seroprevalence studies conducted in schools are beginning to advance our knowledge of school-sARS-CoV-2 transmission among children, staff and families.\textsuperscript{14–16} For example, studies conducted in French\textsuperscript{17} and British\textsuperscript{16} primary schools suggested little evidence of transmission from children to their peers or teachers, while a large Swiss cohort\textsuperscript{18} found minimal clustering of seropositive cases within classes and schools despite a clear increase in seroprevalence in children over a 5-month period of very high transmission.

Further longitudinal seroprevalence studies in settings with diverse transmission dynamics and continually evolving public health interventions, including school and daycare restrictions and the introduction of COVID-19 vaccines, are needed to understand the contribution of schools and daycares for the spread of COVID-19. This is critical not only for decisions about closures, but also for decisions regarding school attendance and the management of school outbreaks through the remainder of this school year and beyond. Moreover, with mounting evidence of the adverse impacts of disruptions to education during the pandemic—for students, families, teachers and staff—it is critical to monitor the mental and emotional health of students and personnel to inform supportive interventions as the COVID-19 situation continues to evolve.\textsuperscript{19–21} This article reports the protocol for the Enfants et COVID-19: Étude de séroprévalence (EnCORE) study, a longitudinal seroprevalence cohort study in primary and secondary schools and daycares in Montreal, Canada.

METHODS AND ANALYSIS

Study design and objectives
This is a longitudinal cohort study of children, adolescents and staff from selected primary and secondary schools and daycares in four neighbourhoods in Montreal, Canada. The study timeline is shown in figure 1. Briefly, children are being enrolled from 20 October 2020 to 15 March 2021 and school and daycare personnel will begin enrolment in late March 2021. The study has two time points of data collection for each participant: baseline (on enrolment) and follow-up (May–June 2021) for children and baseline (March–April 2021) and follow-up (May–June 2021) for personnel.

The study assesses the seroprevalence of SARS-CoV-2 among school and daycare children and personnel at two time points and collects information about COVID-19 tests, symptoms and vaccination, as well as sociodemographic, health and lifestyle outcomes. We aim to address the following objectives:

1. To estimate the seroprevalence of SARS-CoV-2 in school and daycare children and personnel, by neighbourhood and age group.
2. To estimate the risk of seroconversion of SARS-CoV-2 in children from baseline (October 2020–March 2021) to the end of the school year (May–June 2021) and in personnel from baseline (March–April 2021) to the end of the school year (May–June 2021).
3. To describe associations between seroprevalence and sociodemographic and household characteristics, reported COVID-19 symptoms and tests and potential COVID-19 risk factors and prevention efforts.
4. To estimate the prevalence of and changes in health, lifestyle and well-being outcomes in school and daycare children and personnel.
5. To investigate the seroprevalence of SARS-CoV-2 among household contacts of seropositive children participating in the study.

Study setting
Quebec continues to lead the country with the highest provincial crude incidence rate of COVID-19 at 5237 per 100 000 population as of 15 February 2021.\textsuperscript{22} Despite this, Quebec remains committed to prioritising in-person learning during the 2020–2021 school year (September 2020–June 2021), with the only closure being a 1-week or 2-week extension of the December holiday break for primary or secondary schools, respectively. Precautions like stable class groups (where students remain in the same group at all times), mandatory mask wearing for students and alternating in-person and remote attendance for upper secondary students are in place\textsuperscript{23};
However, the decision to keep schools open continues to remain controversial, particularly in hot spots like Quebec’s largest city of Montreal.\(^{24,25}\)

The island of Montreal, home to Canada’s second largest city, has a population of over 1.9 million people.\(^{26}\) The island is divided into the city of Montreal’s 19 arrondissements (boroughs), as well as 15 independent municipalities. For this study, we selected four sentinel neighbourhoods from these 34 boroughs and independent municipalities, based on a derived neighbourhood-level risk strata that reflected both cumulative COVID-19 cases per 100 000 for Montreal for 30 June 2020\(^{27}\) and an average school socioeconomic index (indice de milieu socio-économique, IMSE\(^{28}\)) (figure 2). We identified the following study neighbourhoods based on COVID-19 risk stratum, IMSE stratum and geography (COVID-19 risk–IMSE): West Island (low–low), Mercier-Hochelaga-Maisonneuve (moderate/high–high), Montréal-Nord (high–high) and Plateau (moderate/low–moderate).

**Study population and sample size**

We collaborated with Montreal’s Department of Public Health to seek approvals from the appropriate school boards and daycare associations. Within each of the four neighbourhoods, schools and daycares were selected randomly by the research team followed by subsequent discussions with the school boards. This often led to deviations from the initial sample. The selection of schools also aimed for representation of schools at different IMSE levels within each neighbourhood. The study currently includes 31 daycares, 19 primary schools and 12 secondary schools across the 4 neighbourhoods.

All children and adolescents aged 2–17 years attending a selected daycare or school are invited to participate in the study. Multiple children per household are eligible to participate, as long as they attend one of the participating schools or daycares. The lower bound of 2 years was chosen to simplify specimen collection, as described below. In addition to children and adolescents, all personnel from a sample of participating schools and daycares are eligible to participate. Children and personnel with health conditions that preclude participation in the study are excluded, as well as children whose parent or legal guardian (henceforth referred to as parent) is unable to give informed consent. In addition to school and daycare children and personnel, we will invite all household members of any participating child who obtains a positive SARS-CoV-2 serology result to participate in the study.

We aim to have sufficient power to estimate the prevalence of SARS-CoV-2 among children according to four age groups: 2–4, 5–9, 10–14 and 15–17 years old. Based on available data from Quebec and Ontario,\(^{29}\) we expected a seroprevalence of around 5% for both children and adults. Assuming a loss to follow-up of 30%, a precision of 2% and a confidence level of 95%, a total of 2612 children need to be recruited or 653 per age group or per neighbourhood. For daycare and school personnel, an estimated 831 participants will be needed, assuming a 30% loss to follow-up from enrolment to specimen collection for the baseline and a 15% lost to follow-up at endline.

**Study procedures**

**Recruitment**

An initial invitation email, providing a short description of the study and a link to the study website (https://www.encorestudy.ca), is sent from the director of each participating school or daycare to all parents of currently enrolled children. The study website provides details about the study and participation as well as contact information of the research team. In addition, weekly webinars are hosted to further introduce the study and research team and to respond to any questions parents may have. Parents
and members of personnel can enrol in the study directly from the website, which prompts participants through the steps to read the consent forms and electronically record their consent and the assent of their participating children. In addition, the research team will follow-up by email with the parent of any participating child who receives a positive SARS-CoV-2 serology result, to invite all household members to participate by providing a blood sample for serology testing and contributing information via a household questionnaire. At the time of submission of this article on 5 March 2021, recruitment of children is ongoing, with a total of 1720 children having completed the questionnaire, of which serology results available for 1338. We are in the early stages of recruitment of personnel and household contacts.

Serological samples and testing

One day follow up completion, specimen collection kits for finger prick whole blood samples are delivered to the participant's household. Each kit contains printed directions for collection, storage and mailing for each specific specimen. The specimen collection method is finger prick whole blood on filter paper, where safe contact-activated retractable lancets and filter paper are used by parents for their child's dried blood spot (DBS) sample collection. Expressed blood drops are placed on filter paper that is dried and stored in the fridge until specimen pick-up (within 24 hours of collection). Participants have access to tutorial videos explaining each procedure step-by-step and video conference support from the research team is available on request.

The serostatus of participants is determined by an ELISA that we developed and validated using the receptor-binding domain (RBD) from the spike protein as an antigen. Prior to beginning the study, we successfully validated the ELISA using DBS samples from positive controls (subjects with RT-PCR confirmed SARS-CoV-2 infection and known to be seropositive for anti-SARS-CoV-2 antibodies) and negative controls (SARS-CoV-2 seronegative). Based on the results, the assay had a sensitivity of 95% and specificity of 100%.

On reception in the lab, the Whatman filter papers with DBS were conserved at −20°C and blood was eluted overnight the day before the assay. Samples from the study were processed in 96-well plates with 40 samples from subjects and 7 controls (positive and negative) per plate. A colorimetric reaction determined by optic density (OD) allowed the detection of IgG in the samples and the evaluation of the signal generated by SARS-CoV-2-specific antibodies against the RBD antigen confirmed if subjects were seropositive for this viral pathogen. The OD cut-off for positivity was determined based on the average of OD from negative sera +3 SD.

Parents of children and members of personnel are sent a letter via email that provides their serology result and information about what the result means. All participating children and personnel, regardless of seroprevalence status from the first test, will be retested at the end of the school year. Household contacts of seropositive children will only be tested once.

Survey questionnaires

School and daycare personnel and parents of participating children will complete baseline and follow-up questionnaires through the study website or, if preferred, over the phone with study personnel. At baseline and follow-up, the following information will be collected for all participants: results and dates for all PCR test results, hospitalisations and vaccinations for participants and household members; SARS-CoV-2 symptoms and preventative behaviours in the household and at school/daycare and basic sociodemographic and household characteristics. For the children, lifestyle and mental health information is also collected, including the Strengths and Difficulties Questionnaire Impact Supplement that measures distress and impairment due to emotional and behavioural problems in children and youth. The questionnaire for school and daycare personnel includes validated measures of anxiety (General Anxiety Disorder (GAD)-730), depression (Patient Health Questionnaire (PHQ)-931) and resilience (the Brief Resilience Scale32). The households of children receiving a positive serology result will also be asked to complete a short questionnaire covering household characteristics, potential occupational risks and SARS-CoV-2 symptoms, test results, hospitalisations and vaccination for each household member other than children already participating in the study. Finally, we will review and document public health restrictions present in schools (eg, masks and online learning) and in the community (eg, curfews, lockdowns) during the study period.

Data management

Study data is collected through a secure web platform with access restricted to selected study personnel. The platform is also used to send test results to parents and personnel via email and other study-related information and reminders.

Statistical analysis

We will calculate descriptive statistics of participant sociodemographic, health and COVID-19-related characteristics. Logistic regression with random effects to account for school/daycare clustering will be used to estimate overall seroprevalence, and seroprevalence by neighbourhood, for participating children and personnel. For children, stratified seroprevalence estimates by age and sex will also be calculated and additional clustering by household will be considered. The relative risk of seroconversion between baseline and follow-up will be estimated with logistic regression models using generalised estimating equations to account for school/daycare clustering, controlling for participant and household characteristics. We will investigate the associations of seroprevalence status with sociodemographic and household characteristics, reported COVID-19 symptoms and
potential COVID-19 risk factors and prevention efforts. Associations with emotional and behavioural outcomes in children and mental health outcomes among personnel will also be assessed. Sensitivity analysis that adjust for the sensitivity and specificity of the ELISA test characteristics will be explored. We will compare the sociodemographic characteristics (eg, education, income, race/ethnicity) of parents in our sample to estimates from the 2016 Canadian census for the four neighbourhoods, while population-based data on confirmed COVID-19 cases or seroprevalence will be obtained from provincial and local public health partners.

PATIENT AND PUBLIC INVOLVEMENT
Participants in this study were not involved in the developing of the study design or objectives. The research design and objectives were developed by the investigators of the study and underwent review by the peer review committee of the funder. Parents and partners (daycares, schools, school boards, Montreal Public Health Department) provided advice on participant recruitment and feedback on general aspects of study participation for improvement (eg, DBS collection, questionnaire).

ETHICS AND DISSEMINATION
This study was approved by the research ethics boards of the Université de Montréal (CERSES) and the Centre Hospitalier Universitaire Sainte-Justine. The study was also reviewed and approved by three of the participating school boards: Centre de services scolaire de Montréal, Centre de services scolaire Marguerite-Bourgeoys and the English Montreal School Board and approved by two other participating school boards: Lester B. Pearson School Board and Centre de services scolaire de la Pointe-de-l’Île. Written (electronically) informed consent is obtained from parents or legal guardians of participating children, while written assent (electronically) is obtained from participating children. Participating daycare and school personnel, as well as household members of seropositive children, also provide informed written consent (electronically).

The results of this study will contribute to our knowledge about SARS-CoV-2 transmission in schools and daycares, which is critical for decisions regarding school attendance and the management of school outbreaks through the remainder of this school year and beyond. It will also provide evidence of the pandemic’s adverse impacts on the mental and emotional health of students and personnel to inform supportive interventions as the COVID-19 situation continues to evolve.

Participants and their parents/guardians will have access to their information via the online platform and they will also receive reports summarising the study results after the baseline and at the end of the study. Seroprevalence estimates by neighbourhood and age group will be provided to participating schools and school boards, as well as with public health partners. We will also provide prevalence estimates of emotional and behavioural problems by age group and neighbourhood. Individual data will not be shared with schools nor will school-specific estimates be provided out of for concern for stigmatisation. The results will be published in scientific journals as well as in policy briefs.

Author affiliations
1Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, Quebec, Canada
2Centre for Public Health Research, University of Montreal, Montreal, Quebec, Canada
3Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
4McGill University Health Centre, Montreal, Quebec, Canada
5Montreal Children’s Hospital, Montreal, Quebec, Canada
6Centre Hospitalier de l’Université Laval, Quebec, Quebec, Canada
7Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
8Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada
9Le Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
10Direction régionale de la santé publique de Montréal du CIUSSS du Centre-Sud-de-l’Île-de-Montréal, Montreal, Quebec, Canada
11Institut national de santé publique du Quebec, Quebec, Quebec, Canada
12Department of Microbiology, Infectious Diseases, and Immunology, University of Montreal, Montreal, Quebec, Canada

Acknowledgements We gratefully acknowledge the children, parents and staff for their participation in our study along with the different schools, daycares, school boards and associations for their support. We would also like to acknowledge the various research assistants who support the data collection and dedication to the study.

Contributors The study design and concept were conceived by KZ, MZ, JP, JC, NH, IL, GDS and CQ. KC wrote the statistical analysis plan and conducted the sample size calculation, and MEH and GB developed the lab analysis approach. Other authors (BM, NB, JC, AS, AA, LP, AS-L, GF) provided important feedback on the study design. KZ was responsible for writing the first draft of the manuscript. All authors read, critically revised and approved the final manuscript.

Funding This work was supported by Public Health Agency of Canada through the COVID-19 Immunity Task Force.

Disclaimer The funders had no role in the design of the study, data collection, analysis, interpretation of data and writing of the manuscript.

Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, development, or conduct of reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Britt McKinnon http://orcid.org/0000-0002-3109-5474
REFERENCES

1 UNESCO. UNESCO figures show two thirds of an academic year lost on average worldwide due to Covid-19 school closures, 2021. Available: https://en.unesco.org/news/unesco-figures-show-two-thirds-academic-year-lost-average-worldwide-due-covid-19-school.

2 Vogel L. Have we misjudged the role of children in spreading COVID-19? CMAJ 2020;192:E1102–3.

3 Hyde Z. COVID-19, children and schools: overlooked and at risk. Med J Aust 2020;213:444–6.

4 O’Leary ST. To spread or not to spread SARS-CoV-2—is that the question? JAMA Pediatr 2021;175:559–60.

5 Viner RM, Bonell C, Drake L, et al. Reopening schools during the COVID-19 pandemic: governments must balance the uncertainty and risks of reopening schools against the clear harms associated with prolonged closure. Arch Dis Child 2021;106:111–3.

6 Shkerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr 2020;174:868–73.

7 Rossen LM, Branum AM, Ahmad FB, et al. Excess deaths associated with COVID-19, by age and race and ethnicity — United States, January 26–October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1522–7.

8 Dong Y, Mo X, Hu Y. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020;145:e20200702.

9 Buonsenso D, Valentini P, De Rose C, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: preliminary findings. Pediatr Pulmonol 2021;56:1374–7.

10 Lewis NM, Chu VT, Ye D, et al. Household transmission of SARS-CoV-2 in the United States. Clin Infect Dis 2020;ciaa1166.

11 Tönshoff B, Müller B, Elling R, et al. Prevalence of SARS-CoV-2 infection in children and their parents in southwest Germany. JAMA Pediatr 2021;175:586.

12 Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet 2020;396:313–9.

13 Dunay GA, Barroso M, Woidy M, et al. Age-Dependent seroconversion and low SARS-CoV-2 transmission in children. SSRN Journal 2020.

14 Ulyte A, Radtke T, Abel A, et al. Serorelevance and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study. Int J Public Health 2020;65:1549–57.

15 Theuring S, Thielecke M, van LW. SARS-CoV-2 infection and transmission in school settings during the second wave in Berlin, Germany: a cross-sectional study. medRxiv.

16 Lashani S. Prospective active national surveillance of preschools and primary schools for SARS-CoV-2 infection and transmission in England, June 2020 (eKIDs COVID-19 surveillance in school kids), 2021. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/914700/eKIDs_Phase1Report_01sep2020.pdf

17 Fontanet A, SARS-CoV-2 infection in primary schools in northern France: a retrospective cohort study in an area of high transmission. medRxiv 2020;8:125–7.

18 Ulyte A, Radtke T, Abel A, et al. Clustering and longitudinal change in SARS-CoV-2 zones [Adherence & COVID-19]: prospective cohort study of 55 schools in Switzerland. medRxiv 2021.

19 Hill RM, Rufino K, Kuriyan S, et al. Suicide ideation and attempts in a pediatric emergency department before and during COVID-19. Pediatrics 2021;147:e2020029280.

20 Goldstein E, Ven H, Miller BF. Coronavirus disease 2019 (COVID-19) and mental health for children and adolescents. JAMA Pediatr 2020;174:819–20.

21 Ozamiz-Etxebarria N, Berasategi Sanbo N, Idioiga Mondragon N, Sanxo NB, Mondragon NI, et al. The psychological state of teachers during the COVID-19 crisis: the challenge of returning to face-to-face teaching. Front Psychol 2020;11:620718.

22 Government of Canada. Coronavirus disease 2019 (COVID-19): epidemiology update. undefined, 2021. Available: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html?stat-rate=measures&states=map-pth&ia=2 [Accessed 8 Feb 2021].

23 Government of Quebec. Organization of educational activities in 2020-2021 (COVID-19). Available: https://www.quebec.ca/en/education/organization-educational-activities-covid-19/ [Accessed 8 Feb 2021].

24 Bruemmer R. Should Quebec be closing schools in its COVID-19 hot zones? Montreal Gazette, 2021. Available: https://montrealgazette.com/news/local-news/should-quebec-be-closing-schools-in-its-covid-19-hot-zones.

25 Coletta A. The coronavirus is surging, but Canada is keeping schools open. The Washington post, 2020. Available: https://www.washingtonpost.com/world/the_americas/coronavirus-canada-schools-second-wave/2020/11/02/fbc6c54-0e52-11eb-bbfc-f1b893ecb511_story.html [Accessed 8 Feb 2021].

26 Wikipedia. Montreal. Available: https://en.wikipedia.org/wiki/Montreal#cite_note-cp-2016-CD-10 [Accessed 8 Feb 2021].

27 Montreal Department of Public Health. Situation Du Coronavirus (COVID-19) À Montreal. Available: https://sante.montreal.qc.ca/population/coronavirus-covid-19/situation-du-coronavirus-covid-19-a-montreal/. [Accessed 20 Jun 2020].

28 Ministère de l’Éducation du Québec. Indice de milieu socio-économique (IMSE). Available: http://www.education.gouv.qc.ca/enseignants/aide-et-soutien/milieux-defavorises/agir-avantement/indice-de-milieu-socio-economique-imse/ [Accessed 8 Feb 2021].

29 Office of the chief scientific advisor of Canada. COVID-19 and children: report of a special Task force led by the chief scientific advisor of Canada. Available: https://www.ic.gc.ca/eic/site/063.nsf/vwap/Children-Covid19_Report.pdf/$file/Children-Covid19_Report.pdf.

30 Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7.

31 Kroenke K, Spitzer RL, Williams JB. The PHQ-9. J Gen Intern Med 2001;16:606–13.

32 Smith BW, Dalen J, Wiggins K, et al. The brief resilience scale: assessing the ability to bounce back. Int J Behav Med 2008;15:194–200.